| Literature DB >> 35116922 |
Jun Liu1, Yun-Bo Zhan1, Feng-Jiang Zhang1, Bin Yu1, Wen-Chao Duan1, Wei-Wei Wang2, Li Wang2, Bo Yang1, Zhen-Yu Zhang1.
Abstract
BACKGROUND: Gliomas was the most common primary central nervous system tumors which have an increased morbidity in recent years. And the clinical prognosis of high-grade gliomas (HGG, WHO grade III to IV) was most with an average survival rate of only dozens of months. Many researchers concluded that the level of preoperative albumin-to-globulin ratio (AGR) could predict the clinical outcome of patients with solid malignant tumors.Entities:
Keywords: High-grade glioma (HGG); albumin-to-globulin ratio (AGR); isocitrate dehydrogenase mutation (IDH mutation); prognosis
Year: 2019 PMID: 35116922 PMCID: PMC8798289 DOI: 10.21037/tcr.2019.08.16
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Figure 1Preoperative AGR was related with clinical outcome of patients with high-grade glioma. (A) Survival analysis showed that survival time (OS) of patients with high AGR were longer than patients with low AGR (P<0.001). (B) Survival analysis showed that survival time (PFS) of patients with high AGR were longer than patients with low AGR (P<0.001). AGR, albumin-to-globulin ratio; OS, overall survival; PFS, progression-free-survival.
Univariate analysis of prognostic factors for OS and PFS in high grade glioma patients (n=232)
| Factors | No. of cases | OS | PFS | |||||
|---|---|---|---|---|---|---|---|---|
| 3-year OS (%) | P value | 3-year PFS (%) | P value | |||||
| Sex | ||||||||
| Male | 130 | 19.8 | 0.952 | 13.1 | 0.733 | |||
| Female | 102 | 15.0 | 14.2 | |||||
| Age | ||||||||
| ≤50 | 86 | 29.3 | <0.001* | 19.8 | 0.003* | |||
| >50 | 146 | 10.7 | 9.7 | |||||
| KPS | ||||||||
| ≤80 | 58 | 21.2 | 0.627 | 14.1 | 0.396 | |||
| >80 | 174 | 16.2 | 13.2 | |||||
| Extent of resection | ||||||||
| Gross total | 176 | 17.9 | 0.002* | 13.3 | 0.006* | |||
| Subtotal | 56 | 18.2 | 14.1 | |||||
| RT | ||||||||
| Yes | 177 | 19.6 | <0.001* | 14.2 | 0.001* | |||
| No | 55 | 11.3 | 11.8 | |||||
| CHT | ||||||||
| Yes | 167 | 21.9 | <0.001* | 16.5 | <0.001* | |||
| No | 65 | 5.9 | 4.8 | |||||
| AGR | ||||||||
| ≤1.32 | 28 | 0.0 | <0.001* | 0.0 | <0.001* | |||
| >1.32 | 204 | 20.5 | 15.6 | |||||
| Grade | ||||||||
| III | 59 | 44.6 | <0.001* | 27.9 | <0.001* | |||
| IV | 173 | 7.8 | 8.0 | |||||
| IDH | ||||||||
| IDH wt | 205 | 13.0 | <0.001* | 9.5 | <0.001* | |||
| IDH mut | 27 | 51.3 | 41.3 | |||||
*, P<0.05 showed statistically significant. AGR, albumin-to-globulin ratio; KPS, Karnofsky performance score; RT, postoperative primary radiation therapy; CHT, postoperative primary chemotherapy; IDH, isocitrate dehydrogenase.
Multivariate analysis of prognostic factors for OS and PFS in patients with HGG (n=232)
| Factors | OS | PFS | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Complete resection (yes or no) | 1.965 (1.375–2.807) | <0.001* | 1.741 (1.229–2.466) | 0.002* | |
| Age (≤50 or >50) | 1.184 (0.855–1.641) | 0.310 | 1.167 (0.854–1.596) | 0.333 | |
| RT (yes or no) | 1.127 (0.745–1.705) | 0.571 | 1.095 (0.729–1.644) | 0.663 | |
| CHT (yes or no) | 1.533 (1.026–2.291) | 0.037* | 1.521 (1.027–2.251) | 0.036* | |
| Grade (III or IV) | 2.900 (1.899–4.429) | <0.001* | 2.152 (1.468–3.154) | <0.001* | |
| AGR (≤1.32 or >1.32) | 0.528 (0.347–0.803) | 0.003* | 0.561 (0.369–0.851) | 0.007* | |
*, P<0.05 showed statistically significant. OR, odds ratio; CI, confidence interval; RT, postoperative primary radiation therapy; CHT, postoperative primary chemotherapy; AGR, albumin to globulin ratio; OS, overall survival; PFS, progression free survival; HGG, high-grade glioma.
Multivariate analysis of prognostic factors for OS and PFS in patients with IDH wild-type HGG (n=205)
| Factors | OS | PFS | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Complete resection (yes or no) | 2.023 (1.399–2.925) | <0.001* | 1.821 (1.271–2.610) | 0.001* | |
| Age (≤50 or >50) | 1.259 (0.889–1.784) | 0.195 | 1.213 (0.869–1.693) | 0.256 | |
| RT (yes or no) | 1.261 (0.820–1.939) | 0.290 | 1.293 (0.846–1.976) | 0.235 | |
| CHT (yes or no) | 1.436 (0.952–2.167) | 0.084 | 1.385 (0.923–2.077) | 0.116 | |
| Grade (III or IV) | 2.109 (1.313–3.387) | 0.002* | 1.524 (0.992–2.343) | 0.055 | |
| AGR (≤1.32 or >1.32) | 0.548 (0.359–0.838) | 0.005* | 0.582 (0.382–0.886) | 0.012* | |
*, P<0.05 showed statistically significant. OR, odds ratio; CI, confidence interval; RT, postoperative primary radiation therapy; CHT, postoperative primary chemotherapy; AGR, albumin to globulin ratio; IDH, isocitrate dehydrogenase; OS, overall survival; PFS, progression free survival; HGG, high-grade glioma.
Figure 2Preoperative AGR was related with IDH wild-type HGG. (A,B) Survival analyses showed that among the patients with IDH wild-type HGG, high level of preoperative AGR revealed a better clinical prognosis (OS, P=0.002; PFS, P=0.003). (C,D) There was no statistically significant in HGG patients with IDH mutation in different level of AGR (OS, P=0.153; PFS, P=0.237). AGR, albumin-to-globulin ratio; OS, overall survival; PFS, progression-free-survival; IDH, isocitrate dehydrogenase; HGG, high-grade glioma.